Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.34 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | CSNK1E | P49674 | 2/20 | 0.33 |
| ▸ | BRAF | P15056 | 1/20 | 0.33 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2999644 | 0.92 | BRAF (0.40) | PPARGDGAT2CSNK1EBRAF | |
| SCHEMBL2991607 | 0.91 | PPARG (0.35) | PPARGDGAT2CSNK1EBRAFCNR2 | |
| SCHEMBL1936819 | 0.90 | PPARG (0.35) | PPARGDGAT2CSNK1EBRAFCSNK1D | |
| SCHEMBL1936614 | 0.88 | PPARG (0.37) | PPARGDGAT2CSNK1ECSNK1D | |
| SCHEMBL12330144 | 0.87 | PPARG (0.39) | PPARGDGAT2CSNK1ECSNK1D | |
| SCHEMBL2984692 | 0.86 | BRAF (0.41) | PPARGDGAT2CSNK1EBRAF | |
| SCHEMBL2994355 | 0.85 | BRAF (0.36) | PPARGDGAT2CSNK1EBRAFCNR2 | |
| SCHEMBL2996833 | 0.84 | BRAF (0.35) | PPARGDGAT2CSNK1EBRAFCSNK1D | |
| SCHEMBL13459695 | 0.84 | PPARG (0.38) | PPARGDGAT2CSNK1ECSNK1D | |
| SCHEMBL1936898 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2331502-B1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL MYERS SQUIBB CO (US) | 2016-03-02 | — | — | EP | disclosed |
| US-8536338-B2 | Compounds for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-09-17 | — | — | US | disclosed |
| US-8293909-B2 | Compounds for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-10-23 | — | — | US | disclosed |
| US-20120232099-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2012-09-13 | — | — | US | disclosed |
| US-8198449-B2 | Compounds for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-06-12 | — | — | US | disclosed |
| US-20100184800-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2010-07-22 | — | — | US | disclosed |
| US-20100063068-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2010-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063068-A1 | Compounds for the Treatment of Hepatitis C | HAVCR2, HCCS, SLC10A1 | ACLY 520/4885PPARG 716/4885DGAT2 1365/4885 |
| US-20100184800-A1 | Compounds for the Treatment of Hepatitis C | HAVCR2, HCCS, SLC10A1 | ACLY 520/4885PPARG 716/4885DGAT2 1365/4885 |
| US-20120232099-A1 | Compounds for the Treatment of Hepatitis C | HAVCR2, HCCS, SLC10A1 | ACLY 520/4885PPARG 716/4885DGAT2 1365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.